In this study, FCM of liver biopsies and validation of the frequency of CD8+ PD1+ T cells, an independent risk factor of AIH-overlap NASH, in another cohort of PBMCs could not be performed; therefore, examining the frequency in the liver and another cohort will be a future task. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.